Dashboard
Manage Tickers

ANNX Annexon, Inc.

Nasdaq annexonbio.com


$ 3.20 $ 0.00 (0 %)    

Tuesday, 21-Oct-2025 09:19:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.33 $ 0.00 (0 %)
DIA $ 466.92 $ 0.00 (0 %)
SPY $ 671.18 $ 0.00 (0 %)
TLT $ 92.01 $ 0.00 (0 %)
GLD $ 386.52 $ 0.00 (0 %)
$ 3.16
$ 3.23
$ 3.15 x 100
$ 3.27 x 100
-- - --
$ 1.29 - $ 7.74
2,246,102
na
469.04M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 09-08-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-annexon-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Anne...
08/15/2025 13:06:34

HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $14 price target.

annexon-q2-eps-034-beats-037-estimate
Annexon Q2 EPS $(0.34) Beats $(0.37) Estimate
08/14/2025 20:37:48

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 7....

Core News & Articles
Annexon Announces That The European Medici...
08/07/2025 20:35:02

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, a...

annexon-completes-enrollment-in-pivotal-phase-3-archer-ii-trial-of-vonaprument-for-dry-age-related-macular-degeneration-with-geographic-atrophy
Annexon Completes Enrollment In Pivotal Ph...
07/24/2025 11:05:02

annexon-presents-data-highlighting-outcomes-with-tanruprubart-at-2025-peripheral-nerve-society-annual-meeting
Annexon Presents Data Highlighting Outcome...
05/19/2025 20:06:20

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes S...

coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday
Coinbase To Rally Around 17%? Here Are 10 ...
05/14/2025 12:01:30

hc-wainwright--co-maintains-buy-on-annexon-lowers-price-target-to-14
HC Wainwright & Co. Maintains Buy on Annex...
05/14/2025 10:37:10

HC Wainwright & Co. analyst Andrew Fein maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $20 ...

Core News & Articles
Stanley Black & Decker To Rally Around 24%...
05/13/2025 11:53:23

needham-maintains-buy-on-annexon-lowers-price-target-to-11
Needham Maintains Buy on Annexon, Lowers P...
05/13/2025 10:36:21

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $16 to $11.

annexon-q1-eps-037-misses-029-estimate
Annexon Q1 EPS $(0.37) Misses $(0.29) Esti...
05/12/2025 12:02:50

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.29) by ...

annexons-investigational-drug-shows-rapid-recovery-and-durable-benefit-in-rare-neurological-disorder
Annexon's Investigational Drug Shows Rapid...
04/09/2025 19:20:01

Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 tr...

annexon-says-tanruprubart-met-the-primary-endpoint-demonstrates-rapid-durable-recovery-and-superior-efficacy-in-first-placebo-controlled-phase-3-gbs-trial-showing-significant-improvement-in-motor-function-mobility-and-disability-measures-over-placebo-with-no-new-safety-signals
Annexon Says Tanruprubart Met The Primary ...
04/08/2025 20:55:32

  First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation

annexon-to-present-pivotal-data-on-first-potential-targeted-therapy-for-guillain-barr-syndrome-and-showcases-new-gbs-education-campaign-at-aan-2025-annual-meeting
Annexon To Present Pivotal Data On First P...
04/08/2025 20:08:04

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinica...

reported-earlier-annexon-spotlights-first-in-class-anx005-phase-3-results-for-gbs-and-launches-move-gbs-forward-initiative-at-aan
Reported Earlier, Annexon Spotlights First...
04/04/2025 06:42:24

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, S...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/17/2025 12:11:27

needham-reiterates-buy-on-annexon-maintains-16-price-target
Needham Reiterates Buy on Annexon, Maintai...
03/04/2025 12:04:21

Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.

annexon-q4-eps-033-vs-036-yoy
Annexon Q4 EPS $(0.33) vs $(0.36) YoY
03/03/2025 13:05:32

annexon-presents-anx007-in-geographic-atrophy-at-macula-society-48th-annual-meeting
Annexon Presents ANX007 In Geographic Atro...
02/13/2025 13:43:39

annexon-announces-2025-outlook-anx005-targets-guillain-barr-syndrome-bla-in-h1-2025-anx007-completes-phase-3-enrollment-for-geographic-atrophy-in-h2-2025-anx1502-seeks-clinical-data-in-q1-2025-cash-runway-extends-to-h2-2026
Annexon Announces 2025 Outlook, ANX005 Tar...
01/13/2025 13:46:54

ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA SubmissionANX007 First Potent...

hc-wainwright--co-reiterates-buy-on-annexon-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Anne...
12/17/2024 11:27:59

HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION